---
title: "MVP: Revenue up 9% and net profit after tax rose to $0.6M, driven by Pain Management growth"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296413189.md"
description: "Revenue grew 9% to $42.6 million, led by Pain Management, while net profit after tax rose to $0.6 million. Operating cash flow improved to $5.8 million, and the company remains in a strong net cash position with no dividends declared.Original document: Medical Developments International Limited [MVP] Annual Financial Statement — Aug. 20 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-20T00:10:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296413189.md)
  - [en](https://longbridge.com/en/news/296413189.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296413189.md)
generator: "portal-rs"
---

# MVP: Revenue up 9% and net profit after tax rose to $0.6M, driven by Pain Management growth

Revenue grew 9% to $42.6 million, led by Pain Management, while net profit after tax rose to $0.6 million. Operating cash flow improved to $5.8 million, and the company remains in a strong net cash position with no dividends declared.

Original document: Medical Developments International Limited \[MVP\] Annual Financial Statement — Aug. 20 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [MVP.AU](https://longbridge.com/en/quote/MVP.AU.md)

## Related News & Research

- [OncoZenge UCLA oral mucositis patient engagement study to be presented at ASTRO meeting](https://longbridge.com/en/news/298419720.md)
- [VRTX: Upcoming renal and pain launches, pivotal data, and global expansion drive growth outlook](https://longbridge.com/en/news/298508921.md)
- [Cionic Real-World Evidence Study Examines Quality of Life Across Upper Motor Neuron Conditions](https://longbridge.com/en/news/298445733.md)
- [Opus Genetics reports positive Phase 1/2 low-dose Cohort 1 data for OPGx-BEST1 gene therapy in BEST1 retinal disease](https://longbridge.com/en/news/298445913.md)
- [TENX: Levosimendan benefits PH-HFpEF patients with high disease burden, guiding a refined LEVEL-2 trial](https://longbridge.com/en/news/298456291.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**